BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 30890063)

  • 1. Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry.
    Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
    HIV Clin Trials; 2018 Dec; 19(6):225-234. PubMed ID: 30890063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
    Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
    HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
    Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F;
    J Clin Virol; 2015 Dec; 73():32-35. PubMed ID: 26528903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
    Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
    BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting.
    Gayam V; Hossain MR; Khalid M; Chakaraborty S; Mukhtar O; Dahal S; Mandal AK; Gill A; Garlapati P; Ramakrishnaiah S; Mowyad K; Sherigar J; Mansour M; Mohanty S
    Gut Liver; 2018 Nov; 12(6):694-703. PubMed ID: 29938459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
    Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
    HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlates of HIV sustained viral suppression in HIV/hepatitis C virus coinfected patients: possible role of the hepatitis C virus sustained viral response.
    Bani-Sadr F; Loko MA; Pambrun E; Winnock M; Carrieri P; Gilbert C; Duvivier C; Bouchaud O; Gervais A; Dabis F; Salmon D;
    AIDS; 2014 May; 28(8):1155-60. PubMed ID: 24499953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
    Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
    Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.
    Rockstroh JK; Bhagani S; Hyland RH; Yun C; Dvory-Sobol H; Zheng W; Brainard DM; Ingiliz P; Lutz T; Boesecke C; Nelson M
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):347-353. PubMed ID: 28397698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea.
    Lim DH; Jeong JY; Nam S; Choi J; Kwon HC; Yoon YB; Kim Y; Chin B
    J Korean Med Sci; 2021 Nov; 36(46):e308. PubMed ID: 34845874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals.
    Martinez V; Ta TD; Mokhtari Z; Guiguet M; Miailhes P; Valantin MA; Charlotte F; Bertheau P; Molina JM; Katlama C; Caumes E
    BMC Res Notes; 2012 Jul; 5():180. PubMed ID: 22490728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals.
    Corma-Gómez A; Morano L; Téllez F; Rivero-Juárez A; Real LM; Alados JC; Ríos-Villegas MJ; Vera-Méndez FJ; Muñoz RP; Geijo P; Macías J; Pineda JA;
    AIDS; 2019 Jun; 33(7):1167-1174. PubMed ID: 30845068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
    Loko MA; Bani-Sadr F; Valantin MA; Lascoux-Combe C; Fontaine H; Bonnard P; Gervais A; Bouchaud O; Garipuy D; Quertainmont Y; Vittecoq D; Tehrani MS; Winnock M; Dabis F; Salmon D;
    Antivir Ther; 2012; 17(7):1335-43. PubMed ID: 23052829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infection by HTLV-1 Is Associated With High Levels of Proinflammatory Cytokines in HIV-HCV-Coinfected Patients.
    Brites C; Abrahão M; Bozza P; Netto EM; Lyra A; Bahia F
    J Acquir Immune Defic Syndr; 2018 Feb; 77(2):230-234. PubMed ID: 29084047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
    Bruno G; Saracino A; Scudeller L; Fabrizio C; Dell'Acqua R; Milano E; Milella M; Ladisa N; Monno L; Angarano G
    Int J Infect Dis; 2017 Sep; 62():64-71. PubMed ID: 28728927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting.
    Reiberger T; Obermeier M; Payer BA; Baumgarten A; Weitner L; Moll A; Christensen S; Köppe S; Kundi M; Rieger A; Peck-Radosavljevic M
    Antivir Ther; 2011; 16(6):815-24. PubMed ID: 21900713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients.
    Nelson M; Rubio R; Lazzarin A; Romanova S; Luetkemeyer A; Conway B; Molina JM; Xu D; Srinivasan S; Portsmouth S
    J Interferon Cytokine Res; 2017 Mar; 37(3):103-111. PubMed ID: 28282271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010-2018.
    Simoncini GM; Hou Q; Carlson K; Buchacz K; Tedaldi E; Palella F; Durham M; Li J;
    AIDS Patient Care STDS; 2021 Oct; 35(10):392-400. PubMed ID: 34623891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study.
    Manzardo C; Londoño MC; Castells L; Testillano M; Luis Montero J; Peñafiel J; Subirana M; Moreno A; Aguilera V; Luisa González-Diéguez M; Calvo-Pulido J; Xiol X; Salcedo M; Cuervas-Mons V; Manuel Sousa J; Suarez F; Serrano T; Ignacio Herrero J; Jiménez M; Fernandez JR; Giménez C; Del Campo S; Esteban-Mur JI; Crespo G; Moreno A; de la Rosa G; Rimola A; Miro JM;
    Am J Transplant; 2018 Oct; 18(10):2513-2522. PubMed ID: 29963780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transient liver injury associated with the early recovery of HCV-specific T-cell responses and HCV rebound in HIV-1/HCV coinfected patients undergoing highly active antiretroviral therapy.
    Kang F; Chen W; Zhang X; Nie W; Fu J; Xu X; Zhao P; Zhang X; Li W; Wang FS; Zhang Z; Zhao M
    J Acquir Immune Defic Syndr; 2013 Feb; 62(2):135-42. PubMed ID: 23075912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.